KHI: From Innovation to Implementation

There are currently more than 100,000 people on the waiting list for a kidney, just in the U.S. Innovations in renal replacement therapy could be life-changing for thousands of patients waiting for transplants, or who are not good candidates for transplants.

KHI 4th Annual Stakeholders Meeting (May 2016)

The Kidney Health Initiative (KHI) concluded its 4th Annual Stakeholders' Meeting last week. KHI Project Director Melissa West provides an update on KHI's activities and goals.

In September of 2012, ASN and the FDA launched the Kidney Health Initiative:  the kidney disease burden required a focused effort to create more innovation in key areas of research and practice. Prabir Roy-Chaudhury, MD, PhD, FASN, is Co-Chair of KHI and answered several questions about this initiative.

The Kidney Health Initiative (KHI) promotes much-needed innovation in kidney care. This dynamic and fast-growing public private partnership brings together key members of the kidney community to identify obstacles to innovation and identify solutions that will foster advances in kidney care. Below are a few of the exciting projects KHI supports; learn more about KHI and how it advances research and treatment here.

Clinical Trial Endpoints and Design

The Kidney Health Initiative (KHI), a public-private partnership between the American Society of Nephrology (ASN) and the US Food and Drug Administration (FDA), seeks to encourage innovation and patient safety in kidney disease through its collaborative partnership with the kidney community.